Figure 1From: CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery Serum CA-125 concentrations in patients who developed recurrent EOC (median, 53 U/ml; range, 6 U/ml to 3372 U/ml) were significantly higher than the highest CA-125 level recorded during follow-up in patients who did not develop recurrent disease (median, 11 U/ml; range, 5 U/ml to 87 U/ml; p < 0.001). Back to article page